Intravenous Ketamine for Depression and Suicidality in Borderline Personality Disorder and Borderline Personality Features: A Systematic Review
McMaster University Medical Journal July 26, 2026 Annie Xiong, Sebastian Kolde, Paul Links
Background: Pharmacologic treatment options for borderline personality disorder (BPD) remain limited, and no medication has received regulatory approval for its treatment. Given the high rates of comorbid depression and suicidal ideation in BPD, there is growing interest in novel therapeutic approaches. Ketamine has been approved for treatment-resistant depression and acute suicidality, raising...